Publications by authors named "S Armesto"
Article Synopsis
- The study investigates the link between metabolic dysfunction-associated steatotic liver disease (MASLD) and immune-mediated inflammatory diseases (IMIDs), finding a higher prevalence of advanced liver disease in IMID patients compared to a matched control group.
- Utilizing a case-control design, the research analyzed liver biopsy data and RNA sequencing from patients to identify significant differences in gene expression related to liver disease between IMID and control groups.
- Results indicate that IMIDs not only increase the risk of advanced steatotic liver disease but also suggest a unique pathway for MASLD development in these patients, separate from traditional metabolic factors.
Background: Approved systemic treatment options are limited for pediatric patients with moderate to severe plaque psoriasis.
Objective: To assess the efficacy and safety of apremilast over 16 weeks in pediatric patients with plaque psoriasis.
Methods: SPROUT (NCT03701763) was a phase 3, multicenter, randomized, double-blind, placebo-controlled study of apremilast in patients aged 6-17 years with moderate-to-severe psoriasis (Psoriasis Area and Severity Index [PASI] ≥12, body surface area ≥10%, static Physician Global Assessment [sPGA] ≥3) inadequately controlled by/inappropriate for topical therapy.
Background: Biological therapy dose modification is a common practice in the long-term treatment of plaque psoriasis.
Objective: The objective of the study was to determine prevalence, characteristics of patients, effectiveness, treatment survival of secukinumab dose reduction (SEC-DR) strategy and assess its safety and cost implications.
Methods: A retrospective, observational, multicenter cohort study was conducted in patients with plaque psoriasis treated with secukinumab and up to 2 years of follow-up.